Xtl Biopharmaceuticals (XTLB) Free Cash Flow Growth (3y) (2012 - 2016)
Xtl Biopharmaceuticals (XTLB) Free Cash Flow Growth (3y) (2012 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 31.42% |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 8.63% |
| Dec 31, 2015 | 125.25% |
| Sep 30, 2015 | 2.32% |
| Jun 30, 2015 | -14.17% |
| Dec 31, 2014 | -70.45% |
| Sep 30, 2014 | -22.75% |
| Jun 30, 2014 | -17.60% |
| Mar 31, 2014 | -25.52% |
| Dec 31, 2013 | -16.51% |
| Sep 30, 2013 | -53.64% |
| Jun 30, 2013 | -82.82% |
| Mar 31, 2013 | -59.23% |
| Dec 31, 2012 | -45.10% |
| Sep 30, 2012 | -25.99% |
| Jun 30, 2012 | -44.51% |
| Mar 31, 2012 | 40.29% |